ICMJE DISCLOSURE FORM

| Date: | | | 1/23/2024 | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--|--|
| Your Name: | | | Janwillem WH Kocks | | | |
| Manuscript Title: | | | 10 vragen over hoest | | | |
| Manuscript Number (if known): | | | D7965 | | | |
| In the interest of transparency, we content of your manuscript. "Rela affected by the content of the maindicate a bias. If you are in doubt The author's relationships/activitic epidemiology of hypertension, you that medication is not mentioned | | | rt for the work reported in this manuscript without time limit. For all other items, the time | | | |
| | | | l entities with whom you have this thip or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
| | | | Time frame: Since the initial planning | of the work | | |
| | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | one | Click the tab key to add additional rows. | | |
| | | | Time frame: past 36 month | s | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | AstraZe | nger Ingelheim | | | |
| 3 | Royalties or licenses | | one | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| 4 | Consulting fees | AstraZeneca Boehringer Ingelheim Chiesi | Payments made to institution Payments made to institution Payments made to institution | | |
| | | GSK TEVA MSD COVIS Pharma Jansen | Payments made to institution | | |
| 5 | Payment or honoraria for | □ None | | | |
| lectures, presentations, speakers bureaus, manuscript writing or educational events | | Mundi Pharma ALK-Albello | Payments made to institution Payments made to institution | | |
| 6 | Payment for expert testimony | □ None | | | |
| 7 | Support for attending meetings and/or travel | None | | | |
| 8 | Patents planned, issued or pending | □ None | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None None | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or | European Respiratory Society International Primary Care Respiratory Group CAHAG scientific committee | ERS group chair President, board member Member | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | | |
|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--|--|--|
| | advocacy group, paid or unpaid | Inhalation Institute Netherlands | Board member | | | |
| 11 | Stock or stock options | General Practitioners Research Institute Lothar Medtec | Director, Stocks <5% stocks | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | □ None | | | | |
| 13 | Other financial or non-financial interests | None | | | | |
| Please place an "X" next to the following statement to indicate your agreement: | | | | | | |
| | I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | | | |